India, April 9 -- Forte Biosciences, Inc. (FBRX), a clinical-stage biopharmaceutical company, priced its public offering of 5.71 million shares at $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million.
Following the news, FBRX is currently surging 23.03% to $32.32.
Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, including clinical development of its product candidate. The offering is expected to close on or about April 10, 2026.
The company's lead investigational product candidate is FB-102, in Phase 1 and 2 trials designed for various autoimmune and autoimmune-related indications, including graft-vs-host disease, vitiligo, and ...